Parameters established to determine who can enroll in clinical trials for new multiple myeloma treatments may contribute to underrepresentation of certain racial and ethnic minorities, according to data published in Blood.
Current eligibility criteria tended to cause a higher percentage of patients who identified as Black and as “other” race to be deemed ineligible, whereas those identifying as white and Asian had lower ineligibility rates.
“Our study suggests that, in multiple myeloma clinical trials, some eligibility criteria specified in trial protocols may be contributing
